Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.